These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 23274461)
1. An audience with...Luca Santarelli. Interview by Alexandra Flemming. Santarelli L Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461 [No Abstract] [Full Text] [Related]
2. Is pharma running out of brainy ideas? Miller G Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165 [No Abstract] [Full Text] [Related]
3. Central nervous system drug development, basic, and clinical research: thinking outside the box. Klein DF; Glick ID; Shader RI J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701 [No Abstract] [Full Text] [Related]
4. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents. Cole PE; Schwarz AJ; Schmidt ME Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072 [TBL] [Abstract][Full Text] [Related]
5. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases. Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722 [TBL] [Abstract][Full Text] [Related]
6. Molecular imaging as a de-risking tool: coming into focus? Mullard A Nat Rev Drug Discov; 2013 Apr; 12(4):251-2. PubMed ID: 23535924 [No Abstract] [Full Text] [Related]
8. Quality by design in lead optimization: a new strategy to address productivity in drug discovery. Rossi T; Braggio S Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263 [TBL] [Abstract][Full Text] [Related]
10. What regulatory science can bring for CNS drug development. Gispen-de Wied C; Stoyanova-Beninska V Eur Neuropsychopharmacol; 2015 Jul; 25(7):967-8. PubMed ID: 26024929 [No Abstract] [Full Text] [Related]
11. Securing the future of drug discovery for central nervous system disorders. Andersen PH; Moscicki R; Sahakian B; Quirion R; Krishnan R; Race T; Phillips A; Nat Rev Drug Discov; 2014 Dec; 13(12):871-2. PubMed ID: 25435203 [TBL] [Abstract][Full Text] [Related]
12. Overview of the use of transgenic animals in CNS drug discovery. Nestler EJ; Olivier B Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073 [TBL] [Abstract][Full Text] [Related]
13. Fragment-based lead discovery grows up. Baker M Nat Rev Drug Discov; 2013 Jan; 12(1):5-7. PubMed ID: 23274457 [No Abstract] [Full Text] [Related]
14. Multifunctional drugs as neurotherapeutics. Van der Schyf CJ; Youdim MB Neurotherapeutics; 2009 Jan; 6(1):1-3. PubMed ID: 19110194 [TBL] [Abstract][Full Text] [Related]
15. Organizing for innovation: towards successful translational research. West W; Nightingale P Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820 [TBL] [Abstract][Full Text] [Related]
16. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. Yokley BH; Hartman M; Slusher BS ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461 [TBL] [Abstract][Full Text] [Related]
17. Digital phenotyping approaches and mobile devices enhance CNS biopharmaceutical research and development. Smith DG Neuropsychopharmacology; 2018 Dec; 43(13):2504-2505. PubMed ID: 30267015 [No Abstract] [Full Text] [Related]
18. Axel Unterbeck on memory, cognition and the development of CNS drugs. Interview by Steve Carney. Unterbeck A Drug Discov Today; 2005 Feb; 10(3):165-8. PubMed ID: 15708528 [No Abstract] [Full Text] [Related]
19. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory. Betz UA Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301 [TBL] [Abstract][Full Text] [Related]
20. True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence. Goetghebeur PJ; Swartz JE J Psychopharmacol; 2016 Jul; 30(7):586-94. PubMed ID: 27147593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]